Tranilast antagonizes angiotensin II and inhibits its biological effects in vascular smooth muscle cells

Atherosclerosis

Volumn 121, Issue 2, 1996, Pages 167-173

  Miyazawa, Keiji ^a   Fukuyama, Juichi ^a   Misawa, Keiko ^a   Hamano, Shuichiro ^a   Ujiie, Arao ^a  

^a KISSEI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Angiotensin II receptor; Muscle contraction; PTCA; Restenosis; Tranilast

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN RECEPTOR; ENDOTHELIN 1; LOSARTAN; LOSARTAN POTASSIUM; NORADRENALIN; TRANILAST;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; SMOOTH MUSCLE CONTRACTION; TRANSLUMINAL CORONARY ANGIOPLASTY; VASCULAR SMOOTH MUSCLE;

EID: 0029983254     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/0021-9150(95)05709-9     Document Type: Article

References (31)

1. Dzau VJ. Vascular renin-angiotensin: a possible autocrine or paracrine system in control of vascular function. J Cardiovasc Pharmacol 1984;6:5377-5382.
2. Dzau VJ. Significance of the vascular renin-angiotensin pathway. Hypertension 1986;8:553-559.
3. Morishita R, Gibbons GH, Ellison KE, Lee W, Zhang L, Yu H, Kaneda, Y. Evidence for direct local effect of angiotensin in vascular hypertrophy. In vivo gene transfer of angiotensin converting enzyme. J Clin Invest 1994;94:978-984.
4. Bobik A, Grinpukel S, Little PJ, Grooms A, Jackman G. Angiotensin II and noradrenaline increase PDGF-BB receptors and potentiate PDGF-BB stimulated DNA synthesis in vascular smooth muscle. Biochem Biophys Res Commun 1990;166:580-588.
5. Viswanathan M, Stromberg C, Seltzer A, Saavedra, J.M. Balloon angioplasty enhances the expression of angiotensin II AT1 receptors in neointima of rat aorta. J Clin Invest 1992;90:1707-1712.
6. Panek R, Kaplan C, Overhiser R, Lu G, Major T, Keiser J, Taylor, D. Expression of angiotensin II (Ang II) AT1 and AT2 receptor subtypes in the neointima of rat carotid arteries following balloon injury. Circulation 1992;86(Suppl I):I-168.
7. Rakugi H, Dzau VJ, Pratt RE. Importance of tissue angiotensin converting enzyme (ACE) in neointimal hyperplasia. Circulation 1992;86(Suppl I):I-169.
8. Powell JS, Clozel J, Muller RKM, Kuhn H, Hefti F, Hosang M, Baumgartner HR. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 1989;245:186-188.
9. Kauffman RF, Bean JS, Zimmerman KM, Brown RF, Steinberg MI. Losartan, a nonpeptide angiotensin II (Ang II) receptor antagonist, inhibits neointimal formation following balloon injury to rat carotid arteries. Life Sci 1991;49:PL-223-PL-228.
10. Kawamura M, Terashita Z, Okuda H, Imura Y, Shino A, Nakao M, Nishikawa K. TCV-116, a novel angiotensin II receptor antagonist, prevents intimal thickening and impairment of vascular function after carotid injury in rats. J Pharmacol Exp Ther 1993;266:1664-1669.
11. Griffin SA, Brown WCB, MacPherson F, McGrath JC, Wilson VG, Korsgaard N, Mulvany MJ, Lever AF. Angiotensin II causes vascular hypertrophy in part by a non-pressor mechanism. Hypertension 1991;17:626-635.
12. Dzau VJ, Gibbons GH, Pratt RE. Molecular mechanisms of vascular renin-angiotensin system in myointimal hyperplasia. Hypertension 1991;18(Suppl 4):II100-II105.
13. Azuma H, Banno K, Yoshimura T. Pharmacological properties of N′(3′,4′-dimethoxycinnamoyl) anthranilic acid (N-5′), a new anti-atopic agent. Br J Pharmacol 1976;58:483-488.
14. Isaji M, Nakajoh M, Naito J. Selective inhibition of collagen accumulation by N-(3,4-dimethoxycinnamoyl) anthranilic acid (N-5′) in granulation tissue. Biochem Pharmacol 1987;36:469-474.
15. The TREAT Study Investigators. The impact of tranilast on restenosis following coronary angioplasty: the Tranilast Restenosis Following Angioplasty Trial (TREAT). Circulation 1994;90:1-652.
16. Miyazawa K, Kikuchi S, Fukuyama J, Hamano S, Ujiie A. Inhibition of PDGF-, TGF-β1-induced collagen synthesis, migration, and proliferation in vasucular smooth muscle cells from spontaneously hypertensive rats. Atherosclerosis, 1995;118:213-221.
17. Tang S, Rogg H, Schumacher, R, Dzau VJ. Characterization of nuclear angiotensin-II-binding sites in rat liver and comparison with plasma membrane receptors. Endocrinology 1992;131:374-380.
18. Skalli O, Ropraz P, Trzeciak A, Benzonana C, Gillessen D, Gabbiani G. A monoclonal antibody against α-smooth muscle actin: a new probe for smooth muscle differentiation. J Cell Biol 1986;103:2787-2796.
19. Chiu AT, McCall DE, Price WA, Wong PC, Carini DJ, Duncia JV, Wexler RR, Yoo SE, Johnson AL, Timmermans PBMWM. Nonpeptide angiotensin II receptor antagonists. VII. Cellular and biochemical pharmacology of Dup 753, an orally active antihypertensive agent. J Pharmacol Exp Ther 1990;252:711-718.
20. Wong PC, Hart SD, Zaspel AM, Chiu AT, Ardecky RJ, Smith RD, Timmermans PBMWM. Functional studies of nonpeptide angiotensin II receptor subtype-specific ligands: Dup753 (All-1) and PD123177 (All-2). J Pharmacol Exp Ther 1990;255:584-592.
21. De Gasparo M, Whitebread S, Mele M, Motani AS, Whitcombe PJ, Ramjoue H-P, Kamber B. Biochemical characterization of two angiotensin II receptor subtypes in the rat. J Cardiovasc Pharmacol 1990;16(Suppl 4):531-535.
22. Chang RSL, Lotti VJ. Angiotensin receptor subtypes in rat, rabbit and monkey tissues. Life Sci 1991;49:1485-1490.
23. Bauer PH, Chiu AT, Garrison JC. Dup753 can antagonize the effect of angiotensin II in rat liver. Mol Pharmacol 1991;39:579-585.
24. Herbert J-M, Delisee C, Dol F, Schaeffer P, Cazaubon C, Nisato D, Chatelain P. Effect of SR 47436, a novel angiotensin II AT1 receptor antagonist, on human vascular smooth muscle cells in vitro. Eur J Pharmacol 1994;251:143-150.
25. Timmermans PBMWM, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, Lee RJ, Wexler RR, Saye JAM, Smith RD. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993;45:205-251.
26. Receptor and ion channel nomenclature supplement. Trends Pharmacol Sci 1995;16:13-14.
27. Perlman S, Schambye HT, Rivero RA, Greenlee WJ, Hjorth SA, Schwartz TW. Non-peptide angiotensin agonist: functional and molecular interaction with the AT1 receptor. J Biol Chem 1995;270:1493-1496.
28. Robertson MJ, Dougall IG, Harper D, McKechnie KCW, Leff P. Agonist-antagonist interactions at angiotensin receptors: application of a two-state receptor model. Trends Pharmacol Sci 1994;15:364-369.
29. Griendling KK, Tsuda T, Berk BC, Alexander RW. Angiotensin II stimulation of vascular smooth muscle. J. Cardiovasc Pharmacol 1989;14:527-533.
30. Masaki T, Vane JR, Vanhoutte PM. V. International Union of Pharmacology nomenclature of endothelin receptors. Pharmacol Rev 1994;46:137-142.
31. Bylund DB, Eikenberg DC, Hieble JP, Langer SZ, Lefkowitz RJ, Minneman KP, Molinoff PB, Ruffolo RR Jr, Trendelenburg U. IV. International Union of Pharmacology nomenclature of adrenoceptors. Pharmacol Rev 1994;46:121-136.